When thinking about how best to isolate a bacterium, scientists were often held to the standards of taking time to grow cultures in laboratories, a process involving days or weeks to simply prepare the sample for testing.
Dr Diane Stewart
Diane Stewart has a PhD in chemistry from Brown University, and has had a lengthy career as scientist and manager for numerous scientific instrumentation products including molecular diagnostics instrumentation, nanotechnology, and ion microscopy. Currently she is the product manager for the MiQLab point-of-care system at LexaGene.
She has extensive experience in federal grant writing, negotiating and administration. In addition to program and product management, she is skilled with in-house legal duties have included drafting invention disclosures, tracking patent office actions, patent searching, patent landscape analysis, leading intellectual property review boards, and negotiating legal documentation for collaborations.
What the Heck is a Mycoplasma and Why Doesn’t Anyone Like Them?
The global bioburden testing market for bio-pharma contamination is approximately $10B, with over 350M tests run annually. LexaGene provides early detection for mycoplasma, aiding in validating product quality for biopharmaceutical manufacturers.
Microbial QC Testing in the Manufacture of Biopharmaceuticals
Contamination control of bioprocessing cell lines is essential. The same environments that encourage desirable microbiological growth also encourage growth of undesirable contaminants including yeasts, molds, mycoplasma, bacteria, and viruses.
How qPCR Changed Infectious Disease Detection
Making qPCR molecular diagnostics accessible at point-of-care changed how we detect and treat major infectious diseases.
What is qPCR?
qPCR is used to quickly identify pathogens and antimicrobial resistance markers in a small sample and is indispensable for modern point-of-care molecular diagnostics.